Subject to completion, which Japan-based Takeda expects to occur within a few weeks, Paradigm will become a subsidiary of Takeda Europe Holdings, a wholly owned subsidiary of Takeda. Paradigm will be renamed Takeda Cambridge Limited, and Paradigm's subsidiary in Singapore will be renamed Takeda Singapore Pte Limited.
Paradigm holds a promising pipeline and focuses on the therapy areas of CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity, according to Takeda. The merger replaces Takeda and Paradigm's 2005 CNS therapeutic area alliance.
Yasuchika Hasegawa, president of Takeda, said: “We now have research functions in Japan, the US, Europe, and in Singapore where Paradigm has its subsidiary. This acquisition surely represents our initiatives for establishing global research infrastructures and for pursuing the world's highest standard of productivity, which we believe will support enhancement of our R&D pipeline as source for future growth, and the realization of our goal to become a truly world-class pharmaceutical company.”